Calithera Biosciences Inc. has reinvented itself as a cancer metabolism play since it last raised money. A strong belief in the company's management lured back at least one existing investor in last week's $35 million series D round led by new investor Adage Capital Partners.

New investors Longwood Fund and two undisclosed institutional investors also participated, along with existing investors Morgenthaler Ventures, Advanced Technology Ventures and Delphi Ventures.